Venlafaxine

Speaker 1…and this ties directly into how pain itself can accelerate biological aging. We’re talking about epigenetic clocks and telomere shortening. For example, a study in *GeroScience* 2025, PMID 39847262, found that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy. So, managing pain is crucial.

Speaker 2Absolutely. And that’s where treatments like venlafaxine, an SNRI, come in. It targets descending monoamine pathways, serotonin and norepinephrine, to help relieve certain types of chronic pain. For many, it offers much-needed relief and can improve quality of life, which itself has broad health benefits.

Speaker 1Right. The challenge, then, becomes balancing that benefit against potential long-term risks, especially concerning aging markers and all-cause mortality, which is a major focus of our site.

Speaker 2Exactly. While venlafaxine can be effective for pain management, the evidence on its direct, long-term impact on biological aging—like inflammation or the epigenetic clock—or all-cause mortality, specifically from controlled studies, is less clear. We don't have definitive studies showing it either accelerates or decelerates these processes over years of use.

Speaker 1And we also need to consider potential serious long-term harms. SNRIs can be associated with increased risks of falls, sedation, and cognitive issues in older adults, and dependence is a known factor. These are all things that could indirectly impact overall health and longevity.

Speaker 2So, while we know untreated chronic pain accelerates aging, it's not yet established that venlafaxine specifically *reverses* or *further accelerates* biological aging markers or directly impacts all-cause mortality in the long run. We simply don't have that evidence yet.

Speaker 1It underscores the importance of weighing individual benefits against these potential risks, always under medical supervision.